Patents by Inventor Elisa Pasqua

Elisa Pasqua has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20240092790
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS
    Publication number: 20240092791
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20240092792
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
  • DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20240082223
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 14, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
  • Deuterated N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide
    Patent number: 11814370
    Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 14, 2023
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Matthew D. Cheeseman, A. Elisa Pasqua, Michael J. Tucker
  • Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
    Patent number: 10647678
    Abstract: The present invention relates to compounds of formula I wherein R, R4 and Q are each as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 pathway (HSF1 pathway). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 12, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Keith Jones, Matthew Cheeseman, Nicola Chessum, Elisa Pasqua, Lindsay Evans, Michael Tucker, Birgit Wilding, Ngai Yi Mok
  • DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1-YL)METHYL)QUINOLINE-6-CARBOXAMIDE
    Publication number: 20200039965
    Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 6, 2020
    Inventors: Keith Jones, Matthew D. Cheeseman, A. Elisa Pasqua, Michael J. Tucker